ArticleActa bio-medica : Atenei Parmensis2023
Clinical and immunological features in children with multisystem inflammatory syndrome associated with SARS-CoV-2.
Article in Acta bio-medica : Atenei Parmensis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical analysis of 255 children with multiple serous effusions.Annals of medicine · 2026Article
- Exploratory study of the effect of DHA supplementation on blood fatty acids and inflammatory markers in children with MIS-C.Frontiers in nutrition · 2025Article
- The complex landscape of immune dysregulation in multisystem inflammatory syndrome in children with COVID-19.Life medicine · 2024Review
- Long-term outcomes and immune profiling in children with multisystem inflammatory syndrome (MIS-C).Acta bio-medica : Atenei Parmensis · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimMIS-C is characterized by intense immune activation and increased production of cytokines. The aim of our study was to analyse the changes of cellular and humoral immune responses in children with MIS-C, depending on the severity of the disease.
methodsTo conduct the study, the results of clinical, hematological and immunological parameters in children with severe and extremely severe MIS-C were compared. A total of 50 patients participated in the study, which were divided into 3 groups, of which: 20 children with extremely severe MIS-C treated in the ICU (MIS-C ICU "+"); 15 children with severe MIS-C, but without the need for hospitalization in the ICU (MIS-C ICU "-"); 15 children who had COVID-19 and absence MIS-C (MIS-C "-") made up the control group.
resultsIn patients with MIS-C hospitalized in the ICU, heart and liver damage, hematological changes, and the development of severe complications such as edematous syndrome, polyserositis, DIC, and cardiogenic shock were statistically more common. Both groups of children with MIS-C had CD3+ T-cell lymphopenia and a decrease in CD95 expression. In the group of children with MIS-C hospitalized in the ICU, a significant increase in the relative number of B-lymphocytes, CD3-HLA-DR+ and CD25 and decrease of NK-cells was observed.
conclusionsThe risk of hospitalization in the ICU in children with MIS-C is associated with more profound immune dysregulation, as evidenced by our data. (www.actabiomedica.it).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.